Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
5885 | RAD21 | GSM5252135_BPH511PrPUr_Fcol_3GEX | Human | Prostate | BPH | 3.84e-04 | 3.92e-01 | -0.1833 |
5885 | RAD21 | 047563_1562-all-cells | Human | Prostate | BPH | 5.96e-18 | -1.65e-02 | 0.0791 |
5885 | RAD21 | Dong_P1 | Human | Prostate | Tumor | 1.86e-20 | 5.18e-02 | 0.035 |
5885 | RAD21 | Dong_P3 | Human | Prostate | Tumor | 8.65e-11 | 1.95e-02 | 0.0278 |
5885 | RAD21 | Dong_P5 | Human | Prostate | Tumor | 6.71e-30 | 1.82e-01 | 0.053 |
5885 | RAD21 | GSM5353215_PA_AUG_PB_1B_S2 | Human | Prostate | Tumor | 5.61e-07 | 2.07e-01 | 0.1557 |
5885 | RAD21 | GSM5353216_PA_PB1A_Pool_1_3_S50_L002 | Human | Prostate | Tumor | 7.89e-07 | 5.84e-01 | 0.159 |
5885 | RAD21 | GSM5353217_PA_PB1A_Pool_2_S107_L004 | Human | Prostate | Tumor | 5.77e-07 | 7.71e-01 | 0.156 |
5885 | RAD21 | GSM5353221_PA_PB2A_Pool_1_3_S25_L001 | Human | Prostate | Tumor | 7.58e-19 | 7.34e-01 | 0.1633 |
5885 | RAD21 | GSM5353222_PA_PB2B_Pool_1_3_S52_L002 | Human | Prostate | Tumor | 7.90e-22 | 7.15e-01 | 0.1608 |
5885 | RAD21 | GSM5353223_PA_PB2B_Pool_2_S26_L001 | Human | Prostate | Tumor | 7.05e-14 | 7.02e-01 | 0.1604 |
5885 | RAD21 | GSM5353224_PA_PR5186_Pool_1_2_3_S27_L001 | Human | Prostate | Tumor | 1.36e-06 | 5.05e-01 | 0.1621 |
5885 | RAD21 | GSM5353225_PA_PR5196-1_Pool_1_2_3_S53_L002 | Human | Prostate | Tumor | 2.54e-09 | 6.24e-01 | 0.1619 |
5885 | RAD21 | GSM5353227_PA_PR5199-193K_Pool_1_2_3_S55_L002 | Human | Prostate | Tumor | 3.28e-17 | 5.87e-01 | 0.1602 |
5885 | RAD21 | GSM5353228_PA_PR5199-640K_Pool_1_3_S108_L004 | Human | Prostate | Tumor | 6.89e-10 | 6.67e-01 | 0.1537 |
5885 | RAD21 | GSM5353232_PA_PR5249_T1_S3_L001 | Human | Prostate | Tumor | 2.56e-04 | 1.83e-01 | 0.1439 |
5885 | RAD21 | GSM5353236_PA_PR5251_T1_S7_L001 | Human | Prostate | Tumor | 8.65e-08 | 4.73e-01 | 0.1608 |
5885 | RAD21 | GSM5353240_PA_PR5254_T1_S15_L001 | Human | Prostate | Tumor | 1.23e-10 | 2.86e-01 | 0.1575 |
5885 | RAD21 | GSM5353243_PA_PR5261_T1_S23_L002 | Human | Prostate | Tumor | 1.91e-19 | 4.68e-01 | 0.1545 |
5885 | RAD21 | GSM5353244_PA_PR5261_T2_S24_L002 | Human | Prostate | Tumor | 1.84e-18 | 5.60e-01 | 0.1569 |
Tissue | Expression Dynamics | Abbreviation |
Breast | | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:200125212 | Breast | IDC | positive regulation of chromosome organization | 15/1434 | 82/18723 | 1.28e-03 | 1.35e-02 | 15 |
GO:00330445 | Breast | IDC | regulation of chromosome organization | 26/1434 | 187/18723 | 2.22e-03 | 2.06e-02 | 26 |
GO:00073465 | Breast | IDC | regulation of mitotic cell cycle | 51/1434 | 457/18723 | 4.30e-03 | 3.35e-02 | 51 |
GO:200125221 | Breast | DCIS | positive regulation of chromosome organization | 15/1390 | 82/18723 | 9.37e-04 | 1.06e-02 | 15 |
GO:000734612 | Breast | DCIS | regulation of mitotic cell cycle | 52/1390 | 457/18723 | 1.38e-03 | 1.43e-02 | 52 |
GO:003304412 | Breast | DCIS | regulation of chromosome organization | 26/1390 | 187/18723 | 1.44e-03 | 1.47e-02 | 26 |
GO:00447724 | Breast | DCIS | mitotic cell cycle phase transition | 46/1390 | 424/18723 | 6.16e-03 | 4.39e-02 | 46 |
GO:0010639 | Colorectum | AD | negative regulation of organelle organization | 114/3918 | 348/18723 | 1.41e-07 | 6.49e-06 | 114 |
GO:2001252 | Colorectum | AD | positive regulation of chromosome organization | 35/3918 | 82/18723 | 6.90e-06 | 1.72e-04 | 35 |
GO:0033044 | Colorectum | AD | regulation of chromosome organization | 60/3918 | 187/18723 | 2.25e-04 | 2.94e-03 | 60 |
GO:0007063 | Colorectum | AD | regulation of sister chromatid cohesion | 12/3918 | 21/18723 | 3.02e-04 | 3.62e-03 | 12 |
GO:0007064 | Colorectum | AD | mitotic sister chromatid cohesion | 13/3918 | 28/18723 | 2.22e-03 | 1.75e-02 | 13 |
GO:0007062 | Colorectum | AD | sister chromatid cohesion | 23/3918 | 62/18723 | 2.51e-03 | 1.92e-02 | 23 |
GO:0007346 | Colorectum | AD | regulation of mitotic cell cycle | 119/3918 | 457/18723 | 4.60e-03 | 3.14e-02 | 119 |
GO:0045787 | Colorectum | AD | positive regulation of cell cycle | 85/3918 | 313/18723 | 4.76e-03 | 3.22e-02 | 85 |
GO:0140014 | Colorectum | AD | mitotic nuclear division | 78/3918 | 287/18723 | 6.48e-03 | 4.05e-02 | 78 |
GO:00106392 | Colorectum | MSS | negative regulation of organelle organization | 102/3467 | 348/18723 | 5.36e-07 | 2.05e-05 | 102 |
GO:20012522 | Colorectum | MSS | positive regulation of chromosome organization | 33/3467 | 82/18723 | 3.72e-06 | 1.07e-04 | 33 |
GO:00330441 | Colorectum | MSS | regulation of chromosome organization | 55/3467 | 187/18723 | 1.86e-04 | 2.63e-03 | 55 |
GO:00070631 | Colorectum | MSS | regulation of sister chromatid cohesion | 11/3467 | 21/18723 | 4.85e-04 | 5.65e-03 | 11 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RAD21 | SNV | Missense_Mutation | | c.1522G>C | p.Glu508Gln | p.E508Q | O60216 | protein_coding | tolerated(0.18) | probably_damaging(0.932) | TCGA-A2-A0EW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD |
RAD21 | SNV | Missense_Mutation | novel | c.1627N>T | p.Asp543Tyr | p.D543Y | O60216 | protein_coding | tolerated(0.06) | possibly_damaging(0.67) | TCGA-A7-A6VV-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | CR |
RAD21 | SNV | Missense_Mutation | | c.121N>C | p.Val41Leu | p.V41L | O60216 | protein_coding | deleterious(0.01) | probably_damaging(0.996) | TCGA-A8-A08F-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | 5-fluorouracil | CR |
RAD21 | SNV | Missense_Mutation | | c.268N>T | p.Arg90Trp | p.R90W | O60216 | protein_coding | deleterious(0) | benign(0.167) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RAD21 | SNV | Missense_Mutation | | c.1485N>T | p.Glu495Asp | p.E495D | O60216 | protein_coding | tolerated(0.4) | benign(0.005) | TCGA-C8-A134-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
RAD21 | SNV | Missense_Mutation | | c.1130N>G | p.Ala377Gly | p.A377G | O60216 | protein_coding | tolerated(0.25) | probably_damaging(0.978) | TCGA-D8-A1Y1-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | PD |
RAD21 | insertion | Nonsense_Mutation | novel | c.1641_1642insAGAAGAATAAATTCTAAGTCTTAAACAACAACCTCAAT | p.Asp548ArgfsTer8 | p.D548Rfs*8 | O60216 | protein_coding | | | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RAD21 | SNV | Missense_Mutation | novel | c.185N>A | p.Gly62Glu | p.G62E | O60216 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EA-A3Y4-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
RAD21 | SNV | Missense_Mutation | | c.1450N>C | p.Asp484His | p.D484H | O60216 | protein_coding | deleterious(0.04) | benign(0.157) | TCGA-EK-A2RN-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
RAD21 | SNV | Missense_Mutation | novel | c.426N>C | p.Glu142Asp | p.E142D | O60216 | protein_coding | tolerated(0.15) | probably_damaging(0.956) | TCGA-JW-AAVH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |